Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
139 participants
INTERVENTIONAL
2001-04-30
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fluoxetine for Anxious Children
NCT00000381
Treatment for Anxiety in Children
NCT00000389
Fluoxetine vs CBT in Childhood Anxiety Disorders
NCT04760275
St. John's Wort Versus Placebo in Social Phobia
NCT00035412
D-Cycloserine Enhancement of Exposure in Social Phobia
NCT00633984
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Social Effectiveness Therapy for Children
Social Effectiveness Therapy for Children includes social skills training, peer generalization experiences and exposure therapy
Social Effectiveness Therapy for Children (SET-C)
Fluoxetine
Fluoxetine given in 10mg doses, up to 40 mg as tolerated
Fluoxetine
Pill placebo
Capsules identical to fluoxetine given in "10 mg." doses up to 40 mg.
Pill Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Social Effectiveness Therapy for Children (SET-C)
Fluoxetine
Pill Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Schizophrenia
* Major Depression
* IQ of less than 80
* Medical conditions contraindicating use of fluoxetine
8 Years
16 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
University of Central Florida
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Deborah Beidel
Professor of Psychology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maryland Center for Anxiety Disorders
University of Maryland, College Park, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Beidel DC, Turner SM, Sallee FR, Ammerman RT, Crosby LA, Pathak S. SET-C versus fluoxetine in the treatment of childhood social phobia. J Am Acad Child Adolesc Psychiatry. 2007 Dec;46(12):1622-32. doi: 10.1097/chi.0b013e318154bb57.
De Los Reyes A, Alfano CA, Beidel DC. Are clinicians' assessments of improvements in children's functioning "global"? J Clin Child Adolesc Psychol. 2011;40(2):281-94. doi: 10.1080/15374416.2011.546043.
De Los Reyes A, Alfano CA, Beidel DC. The relations among measurements of informant discrepancies within a multisite trial of treatments for childhood social phobia. J Abnorm Child Psychol. 2010 Apr;38(3):395-404. doi: 10.1007/s10802-009-9373-6.
Other Identifiers
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.